Differentiation of cytomegalovirus-specific CD8(+) T cells in healthy and immunosuppressed virus carriers.
During immunosuppression, cytomegalovirus (CMV) can reactivate and cause serious clinical problems. Normally, abundant virus replication is suppressed by immune effector mechanisms. To study the interaction between CD8(+) T cells and persisting viruses, frequencies and phenotypes of CMV-specific CD8(+) T cells were determined in healthy individuals and compared to those in renal transplant recipients. In healthy donors, function of circulating virus-specific CD8(+) T cells, as measured by peptide-induced interferon gamma (IFN-gamma) production, but not the number of virus-specific T cells enumerated by binding of specific tetrameric peptide/HLA complexes, correlated with the number of CMV-specific IFN-gamma-secreting CD4(+) helper T cells. Circulating CMV- specific CD8(+) T cells did not express CCR7 and may therefore not be able to recirculate through peripheral lymph nodes. Based on coexpression of CD27 and CD45R0 most CMV-specific T cells in healthy donors appeared to be memory-type cells. Remarkably, frequencies of CMV-specific CD8(+) T cells were significantly higher in immunosuppressed individuals than in healthy donors. In these patients CMV-specific cells predominantly had an effector phenotype, that is, CD45R0(+)CD27(-)CCR7(-) or CD45RA(+)CD27(-)CCR7(-) and contained both granzyme B and perforin. Our data show that in response to immunosuppressive medication quantitative and qualitative changes occur in the CD8(+) T-cell compartment. These adaptations may be instrumental to maintain CMV latency. (Blood. 2001;98:754-761)
Gamadia
L E
LE
Renal Transplant Unit, Department of Internal Medicine, Academic Medical Center, The Netherlands Cancer Institute, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. l.e.gamadia@amc.uva.nl
Rentenaar
R J
RJ
Baars
P A
PA
Remmerswaal
E B
EB
Surachno
S
S
Weel
J F
JF
Toebes
M
M
Schumacher
T N
TN
ten Berge
I J
IJ
van Lier
R A
RA
D000328:Adult; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology* / Q000821:virology*; D016022:Case-Control Studies; D002454:Cell Differentiation / Q000276:immunology*; D003587:Cytomegalovirus / Q000254:growth & development / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000097:blood / Q000276:immunology; D053804:Granzymes; D006680:HLA Antigens / Q000378:metabolism; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology*; D016130:Immunophenotyping; D016030:Kidney Transplantation / Q000276:immunology; D008137:Longitudinal Studies; D011971:Receptors, Immunologic / Q000378:metabolism; D054340:Receptors, KIR; D012697:Serine Endopeptidases / Q000378:metabolism; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7 / Q000378:metabolism; D014775:Virus Activation
D006680:HLA Antigens; D011971:Receptors, Immunologic; D054340:Receptors, KIR; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7; C509213:GZMB protein, human; D053804:Granzymes; D012697:Serine Endopeptidases